The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland

Value in Health

Volumn 5, Issue 5, 2002, Pages 405-421

  Orlewska, Ewa ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NONE   (Poland)

Author keywords

Chronic hepatitis B8cost effectiveness analysis; Interferon alpha; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ALGORITHM; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; IMMUNOTHERAPY; LIFE EXPECTANCY; NEUTROPENIA; OUTCOMES RESEARCH; POLAND; PRIORITY JOURNAL; PSYCHOSIS; SEROCONVERSION; SUICIDAL BEHAVIOR; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0036742716     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.55147.x     Document Type: Article

References (66)

1. Gładysz A, Juszczyk J. Leczenie chorób wǎtroby [Therapy of liver diseases] (1st ed.) Wroclaw, Poland: Volumed, 1996.
2. World Health Organization. Hepatitis B fact sheet WHO/204 [Internet]. Geneva: The Organization; 2000 Oct revised [cited]. Available from: www.who.int/inf-fs/en/fact204.html
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-44.
4. Magdzik W. Epidemiologia wirusowych zapaleń wǎtroby typu B i C w Polsce z uwzglȩdnieniem dzieci [Epidemiology of type B and C viral hepatitis in Poland including children]. Hepatol Polska 1997;4:S5-9.
5. Juszczyk J, Gładysz A. Viral hepatitis in Poland. Hepatol Polska 1997;4:65-8.
6. Hoofnagle JH, Dusheiko GM, Seelf LB, et al. Seroconversion from hepatitis e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8.
7. Alward WL, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1995;151:604-9.
8. Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980;79:195-9.
9. Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-9.
10. Bonino F, Rosina F, Rizzeto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90:1268-73.
11. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBeAg in chronic hepatitis type B. Hepatology 1986;6:167-72.
12. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1097;92: 1839-43.
13. Juszczyk J. Wirusowe zapalenia wǎtroby [Viral hepatitis] (1st ed.) Warszawa: PZWL, 1999.
14. The CASL Hepatitis Consensus Group. Treatment of chronic viral hepatitis with alpha-interferon: a consensus conference report. Can J Infect Dis 1994;5:107-12.
15. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
16. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212.
17. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
18. Villeneuve JP, Bilodeau M, Fenyves D. Suppression of hepatitis B virus replication by lamivudine results in improvement of liver function in patients with severe cirrhosis. Hepatology 1997;26(Suppl): 430A.
19. Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997;12:843-53.
20. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
21. Lau DT, Everhardt J, Kleiner DL, et al. Long term follow-up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology 1997;113:1660-7.
22. Hope RL, Welman M, Dingley J, et al. Interferon alpha for chronic active hepatitis B, long term follow-up of 62 patients: outcomes and predictors of response. Med J Aust 1995;162:8-11.
23. Tine F, Liberati A, Craxi A, et al. Interferon treatment in patients with chronic hepatitis B: a metaanalysis of the published literature. J Hepatol 1993;18:154-62.
24. Burt MJ, Ross AG, Schoeder BA, et al. Evaluation of alpha interferon for the treatment of chronic hepatitis B infection in Christchurch. N Z Med J 1996;109:162-4.
25. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998;59:563-78.
26. Krogsgaard D. The long-term effect of treatment with interferon alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group, The European Study Group on Viral Hepatitis (EUROHEP) Executive Team on Antiviral Treatment. J Viral Hepat 1998;5:389-97.
27. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B-a meta-analysis. Ann Intern Med 1993; 199:312-23.
28. Lampertico P, Del Ninno E, Maniz A, et al. A randomised, controlled trial of 24-month course of interferon alpha 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:1621-5.
29. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha. Gastroenterology 1993; 105:1833-8.
30. Lok AS, Lai CL, Wu PC, et al. Long-term follow-up in a randomised controlled trial of recombinant alpha2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;II:298-302.
31. Guptan RK, Thakur V, Malhortra V, et al. Low-dose recombinant interferon therapy in anti HBe-positive chronic hepatitis B in Asian Indians. J Gastroenterol Hepatol 1998;13:675-9.
32. Zhang X, Zoulim F, Haberseber I, et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
33. Krogsgaard K, Bindsley N, Christenses E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment: results based on individual patient data from 10 clinical controlled trial. J Hepatol 1994;21:646-55.
34. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon α-2b in patients with chronic hepatitis B, who previously failed interferon therapy. 49th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; 1998 Nov 6-10; Chicago, IL. Hepatology 1998; 28(4 Suppl Pt 2):A388.
35. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562-8.
36. Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
37. Perillo RP, Schalm SW, Schiff ER, et al. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine. Hepatology 1999;28:317A.
38. Chien RN, Liaw YN, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-4.
39. Heatcote J, Schalm SW, Cianciara J, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. 33rd Annual Meeting and Postgraduate Courses of the European Association for the Study of the Liver; 1998 Apr 15-18; Lisbon, Portugal. J Hepatol 1998;28:S43.
40. Koorenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after interferon α therapy. Ann Intern Med 1991;114: 629-34.
41. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
42. Schiff E, Cianciara J, Kowdley K, et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. 49th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; 1998 Nov 6-10; Chicago, IL. Hepatology 1998;28:A163.
43. Schiff E, Cianciara J, Karayalcin S, et al. Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB). 35th Annuual Meeting of the European Association for the Study of the Liver; 2000 Apr 28-May 2; Rotterdam, The Netherlands. J Hepatol 2000;32:S99.
44. Song BC, Suh DJ, Lee HC, et al. Seroconversion after lamivudine treatment is not durable in chronic hepatitis. 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; 1999 Nov 5-9; Dallas, TX. Hepatology 1999;30:A348.
45. Dienstag J, Schiff E, Wright T, et al. Lamivudine treatment for one year in previously untreated US hepatitis B patients. histological improvement and hepatitis e-antigen (HBeAg) seroconversion. Digestive Disease Week and 99th Annual Meeting of the American Gastroenterological Association; 1998 May 16-22; New Orleans, LA. Gastroenterology 1998;114A:1235.
46. Goodman Z, Dhillon AP, Wu PC, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 1999;30:S59.
47. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-8.
48. Brook MG, Petrovic L, McDonald JA, et al. Histological improvement after antiviral treatment for chronic hepatitis B virus infection. J Hepatol 1989;8:218-25.
49. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
50. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
51. Leung NWY, Lai CL, Chang TT. Three year lamivudine therapy in chronic HBV. J Hepatol 1999;30:S59.
52. Liaw YH, Lai CL, Leung NWY, et al. Two years lamivudine therapy in chronic hepatitis B infection. results of a placebo-controlled multicentre study in Asia. Digestive Disease Week and 99th Annual Meeting of the American Gastroenterological Association; 1998 May 16-22; New Orleans, LA. Gastroenterology 1998;114:1289.
53. Hoofnagle JH, Di BAM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
54. Leung N, Dienstag J, Schieff E, et al. Clinical safety profile of lamivudine treatment in large cohort of hepatitis B patients. 49th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; 1998 Nov 6-10; Chicago, IL. Hepatology 1998;28:587A.
55. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six month randomised dose-ranging study. Gastroenterology 1997;113:1258-63.
56. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. Ann Intern Med 1984;101:613-6.
57. Warsztaty hepatologiczne; 2000 XI 24-25; Falenty kolo Warszawy [Hepatological Workshop of the Hepatological Section of the Polish Society for Infectious Diseases; 24-25 Nov 2000; Falenty by Warsaw].
58. Cennik hurtowni farmaceutycznej Prosper 2002 ][Prosper pharmaceutical wholesales price-list 2002] [Internet]. Prosper [cited 2002 Jan]. Available from: www.prosper.pl/oferta/index.html
59. Taryfikator Usług Medycznych 2002. [Medical Services Schedule 2002] [Internet]. Available from: www.kasa-chrych.lodz.pl/Konkurs2002/cennik. html
60. Główny Urzǎd Statystyczny [Life table of Poland] [Internet]. [cited 2002 Jan]. Polish Official Statistics. Programme of Statistical Survey Publications, Warsaw, Poland. Available from: www.stat.gov.pl/serwis/nieregularne/trwanie_tabl.xls
61. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998;61:238-42.
62. Dushieko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995;22:1863-73.
63. Crowley SJ, Tognarini D, Desmond P, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000;17:409-27.
64. Sarin SK. Hepatitis B mutants: prevalence, significance and therapy [editorial]. Hepatic World 1998;3:1.
65. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
66. Honkoop P, de Man RA, Niesters H, et al. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998;29:510-4.